Navigation Links
Envisioning the future of neuroscience

Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplinesincluding chemistry, engineering, physics, molecular biology, neurosciences and imaging sciencesto promote the emerging field of molecular neuroimaging.

"Molecular Imaging Symposium: Envisioning the Future of Neuroscience," which is taking place May 6-7 at the Natcher Auditorium of the National Institutes of Health (NIH) in Bethesda, Md., has attracted physicians and researchers from the basic science, translational and clinical communities, including a number of scientists-in-training. The meeting focuses on advances in targeted multimodality imaging of the central nervous system (CNS), including imaging of the bloodbrain barrier, tumors, neuroreceptors, stem cells, adoptive immunotherapies and other biological processes relevant to the CNS.

This morning, the meeting kicked off with a keynote speech by William Pardridge, M.D., from the University of California, Los Angeles. Partridge discussed the design and engineering of molecular "Trojan horses" as a way to smuggle biopharmaceuticals past the blood-brain barrier.

The keynote speech was followed by the first of four sessions for the day, each of which began with a lecture and concluded with a panel discussion and question and answer session. The first session provided an overview and introduction to molecular neuroimaging, going into detail about the molecular imaging techniques now in clinical use, including PET, SPECT, preclinical and intraoperative imaging.

"One of the main objectives of the meeting is to show the scientific and clinical communities the great potential behind targeted multimodality molecular neuroimaging," said Michelle S. Bradbury, Ph.D., M.D., of the Sloan-Kettering Institute for Cancer Research, New York, and co-chair of the program committee. "By wedding state-of-the-art imaging technologies with novel molecular and particle probes designed to penetrate the blood-brain barrier, there is unprecedented capability to study brain metabolism, function and pathophysiology, as well as to apply this new knowledge to improving medicine and patient outcomes.

The second session investigated nanoparticles and their potential for diagnosing and treating diseases of the brain and central nervous system. The second keynote speech of the day, "Imaging the Addicted Brain," given by Nora Volkow, M.D., director of the National Institute on Drug Abuse/NIH, Bethesda, Md., discussed the role of molecular imaging in the cutting edge research now underway to elucidate the biology of addiction.

During the sessions that took place in the afternoon, the focus shifted to more selected topics, such as those addressing the evolving areas of blood-brain barrier delivery and cellular therapies for treating brain tumors. For example, the third session covered successes and challenges in crossing the blood-brain barrier to deliver imaging and therapeutic agents. The final session of the day explored stem cell therapeutics and adoptive immunotherapies for brain tumors.

"It is increasingly important to find and implement new ways of studying the brain," said MICoE President Henry F. VanBrocklin, Ph.D., professor of radiology and director of radiopharmaceutical research in the Center for Functional and Molecular Imaging at the University of California, San Francisco, and a member of the symposium's program committee. "Molecular imaging can improve our understanding and management of critical central nervous system pathophysiological processes, such as neurodegeneration, brain tumors and psychiatric diseases."

This evening, a banquet and abstracts award presentation will recognize research by some of the outstanding new researchers in the field. Michael Phelps, Ph.D., University of California, Los Angeles, will speak at the dinner and focus on translating metabolic assays into molecular imaging diagnostics.

The agenda for tomorrow, the second day of the meeting, includes sessions that provide new information on imaging brain tumors, imaging biomarkers for the diagnosis of dementia and a final session on psychiatric and neurobehavorial research. Attendees will gain an understanding of how research in molecular neuroimaging can be applied to patient care.


Contact: Amy Shaw
Society of Nuclear Medicine

Related medicine news :

1. Wyatt Matas & Associates Releases White Paper on Future Home Healthcare Business Model
2. CAP Leaders, Policymakers Convene on the Future of Pathology
3. Researchers find future temperatures could exceed livable limits
4. Genome Scan Gives Man Insight Into Future Health Risks
5. Henry Ford Health System goes radical: Creating the hospital of the future
6. Delayed retirement among Americans may bolster future of Social Security and Medicare, study finds
7. Summit Medical Group Prepares Physicians for Future Leadership
8. Unprecedented AIUM training guidelines speak to future of musculoskeletal ultrasound
9. Future Apps Releases Major Update to its Popular iPhone Text to Speech App Speak it
10. Medicines Future Could Lie in Each Patients Genome
11. Brain scans could be marketing tool of the future
Post Your Comments:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: